Allergan plc (NYSE:AGN)went up by 1.12% from its latest closing price when compared to the 1-year high value of $197.00 and move down -18.79%, while AGN stocks collected +2.57% of gains with the last five trading sessions. Press Release reported on 09/10/19 that Allergan Shareholder Meetings Scheduled for October 14, 2019
Allergan plc (NYSE:AGN) Worth an Investment?
Allergan plc (NYSE: AGN) The 36 Months beta value for AGN stocks is at 1.65, while of the analysts out of 0 who provided ratings for Allergan plc stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $181.67 which is $14.29 above current price. AGN currently has a short float of 2.60% and public float of 327.13M with average trading volume of 4.97M shares.
AGN Market Performance
AGN stocks went up by 2.57% for the week, with the monthly jump of 4.53% and a quarterly performance of 35.63%, while its annual performance rate touched -12.34%. The simple moving average for the period of the last 20 days is 3.48% for AGN stocks with the simple moving average of 12.52% for the last 200 days.
Analysts’ Opinion on Allergan plc (NYSE:AGN)
Many brokerage firms have already submitted their reports for AGN stocks, with Guggenheim repeating the rating for AGN shares by setting it to “Neutral”. The predicted price for AGN socks in the upcoming period according to Guggenheim is $59 based on the research report published on August 7, 2019.
SVB Leerink, on the other hand, stated in their research note that they expect to see AGN stock at the price of $59. The rating they have provided for AGN stocks is “Mkt Perform” according to the report published on July 18, 2019.
Bernstein gave “ Mkt Perform” rating to AGN stocks, setting the target price at $59 in the report published on July 16, 2019.
AGN Stocks 2.42% Far from 50 Day Moving Average
After a stumble in the market that brought AGN to its low price for the period of the last 52 weeks, Allergan plc was unable to take a rebound, for now settling with -15.82% of loss for the given period.
The stock volatility was left at 1.15%, however, within the period of a single month, the volatility rate increased by 1.12%, while the shares surge at the distance of +3.69% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -1.00% lower at the present time.
In the course of the last 5 trading sessions, AGN went up by +2.57%, which changed the moving average for the period of 200 days to the total of +7.46% of gains for the stock in comparison to the 20-day moving average settled at $160.56. In addition, Allergan plc saw 24.08% in overturn over the period of a single year with a tendency to cut further gains.
AGN Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Allergan plc (AGN), starting from SAUNDERS BRENT L, who bought 1,760 shares at the price of $143.67 back on Mar 07. After this action, Rushing now owns 170,666 shares of Allergan plc, valued at $252,858 with the latest closing price.
WALSH MATTHEW M, the EVP, Chief Financial Officer of Allergan plc, bought 1,000 shares at the value of $157.00 during a trade that took place back on Nov 16, which means that WALSH MATTHEW M is holding 26,416 shares at the value of $157,000 based on the most recent closing price.
AGN Stock Fundamentals
The current profitability levels are settled at +2.11 for the present operating margin and +44.18 for gross margin. The net margin for Allergan plc stands at -32.28. Total capital return value is set at 0.35, while invested capital returns managed to touch -5.43. Equity return holds the value -13.20%, with -8.50% for asset returns.
Based on Allergan plc (AGN), the company’s capital structure generated 36.55 points for debt to equity in total, while total debt to capital is set at the value of 26.77. Total debt to assets is settled at the value of 23.38 with long-term debt to equity ratio rests at 35.21 and long-term debt to capital is 25.79.
EBITDA value lies at +1.93 B with total debt to EBITDA carrying the value of 3.36. The value for Enterprise to Sales is 4.79 with debt to enterprise value settled at 0.36. The receivables turnover for Allergan plc is 5.34 with the total asset turnover at the value of 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.